Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
CX-2029 by CytomX Therapeutics for Prostate Cancer: Likelihood of Approval
CX-2029 is under clinical development by CytomX Therapeutics and currently in Phase II for Prostate Cancer. According to GlobalData, Phase...